title: Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group.
abstract: BACKGROUND
  Th2 cytokines play an important part in the pathogenesis of asthma. Our aim was to study the effect of suplatast tosilate, a selective Th2 cytokine inhibitor, on asthma control and asthma exacerbations during reduction of inhaled corticosteroid dose in patients with steroid-dependent asthma.
  
  
  METHODS
  85 patients with moderate to severe asthma taking high doses (> or = 1500 microg per day) of inhaled beclometasone dipropionate, were assigned suplatast tosilate (100 mg three times daily) or placebo for 8 weeks in a double-blind, randomised, parallel-group, multicentre trial. During the first 4 weeks, other medications remained unchanged (add-on phase); during the next 4 weeks, the doses of beclometasone were halved (steroid-reduction phase). Main outcome measures were pulmonary function, asthma symptoms, and use of beta2-agonists.
  
  
  RESULTS
  Data were available from 77 patients. During the add-on phase, suplatast tosilate treatment, compared with placebo, was associated with higher forced expiratory volume in 1 s (mean difference between groups for changes from baseline at week 4, 0.20 L [95% CI 0.16-0.24], p=0.043), morning peak expiratory flow (18.6 L/min [14.1-23.1], p=0.037), and less diurnal variation in peak expiratory flow rate, asthma symptom scores (7.1 [6.6-7.6], p=0.029), and serum concentrations of eosinophil cationic protein and IgE. In the steroid-reduction phase, pulmonary function, asthma symptoms, and use of beta2-agonist deteriorated significantly more in the placebo group than in the suplatast group.
  
  
  CONCLUSIONS
  Treatment with a Th2 cytokine inhibitor in steroid-dependent asthma improves pulmonary function and symptom control, and allows a decrease in dose of inhaled corticosteroid without significant side-effects. Some improvements in pharmacokinetics are, however, needed.
authors.affiliation: First Department of Medicine, Tokyo Women's Medical University School of Medicine, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Tamaoki
authors.forename: M
authors.initials: M
authors.lastname: Kondo
authors.forename: N
authors.initials: N
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Aoshiba
authors.forename: E
authors.initials: E
authors.lastname: Tagaya
authors.forename: J
authors.initials: J
authors.lastname: Nakata
authors.forename: K
authors.initials: K
authors.lastname: Isono
authors.forename: A
authors.initials: A
authors.lastname: Nagai
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001190:Arylsulfonates / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D002940:Circadian Rhythm; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D013452:Sulfonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D018418:Th2 Cells
chemical_list: D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D001190:Arylsulfonates; D016207:Cytokines; D013452:Sulfonium Compounds; C073028:suplatast tosilate; D001507:Beclomethasone